Literature DB >> 3889368

An avirulent G1 glycoprotein variant of La Crosse bunyavirus with defective fusion function.

F Gonzalez-Scarano, R S Janssen, J A Najjar, N Pobjecky, N Nathanson.   

Abstract

La Crosse virus, a member of the California serogroup of the family Bunyaviridae, causes encephalitis in humans and laboratory rodents. A variant virus (V22) selected with a monoclonal antibody against the large (G1) glycoprotein showed diminished neuroinvasiveness after peripheral inoculation. This variant has an alteration in its fusion function, requiring a lower pH for the activation of fusion and demonstrating reduced efficiency of cell-to-cell fusion of BHK-21 cultures. V22 was studied in detail following the infection by intraperitoneal or intracerebral routes in suckling, weanling, or adult CD-1 mice. It exhibited a marked reduction in its ability to replicate in striated muscle and to produce viremia; however, after intracerebral injection V22 virus replicated almost as rapidly in brain as its parent, La Crosse virus. V22 virus thus represents an example of reduced neuroinvasiveness associated with an alteration at a specific epitope of the G1 glycoprotein. This same epitope also influences the fusion activity of the glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3889368      PMCID: PMC254862     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines.

Authors:  J F Kearney; A Radbruch; B Liesegang; K Rajewsky
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

2.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

3.  Two disulfide-linked polypeptide chains constitute the active F protein of paramyxoviruses.

Authors:  A Scheid; P W Choppin
Journal:  Virology       Date:  1977-07-01       Impact factor: 3.616

4.  Purification of the fusion protein of Sendai virus: analysis of the NH2-terminal sequence generated during precursor activation.

Authors:  M J Gething; J M White; M D Waterfield
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

5.  The entry into host cells of Sindbis virus, vesicular stomatitis virus and Sendai virus.

Authors:  D P Fan; B M Sefton
Journal:  Cell       Date:  1978-11       Impact factor: 41.582

6.  La Crosse virus G1 glycoprotein undergoes a conformational change at the pH of fusion.

Authors:  F Gonzalez-Scarano
Journal:  Virology       Date:  1985-01-30       Impact factor: 3.616

7.  Activation of the Sendai virus fusion protein (f) involves a conformational change with exposure of a new hydrophobic region.

Authors:  M Hsu; A Scheid; P W Choppin
Journal:  J Biol Chem       Date:  1981-04-10       Impact factor: 5.157

8.  Virulence and persistence of three prototype strains of mumps virus in newborn hamsters.

Authors:  J S Wolinsky; W G Stroop
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

9.  M viral RNA segment of bunyaviruses codes for two glycoproteins, G1 and G2.

Authors:  J R Gentsch; D L Bishop
Journal:  J Virol       Date:  1979-06       Impact factor: 5.103

10.  Structural proteins of La Crosse virus.

Authors:  J F Obijeski; D H Bishop; F A Murphy; E L Palmer
Journal:  J Virol       Date:  1976-09       Impact factor: 5.103

View more
  19 in total

1.  Comparative analysis of G1 glycoprotein-coding sequences of Cache Valley virus (Bunyaviridae: Bunyavirus) isolates.

Authors:  C L Brockus; P R Grimstad
Journal:  Virus Genes       Date:  2001-03       Impact factor: 2.332

2.  Neuroattenuation of an avirulent bunyavirus variant maps to the L RNA segment.

Authors:  M J Endres; C Griot; F Gonzalez-Scarano; N Nathanson
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

3.  Genetic basis for altered pathogenesis of an immune-selected antigenic variant of reovirus type 3 (Dearing).

Authors:  K M Kaye; D R Spriggs; R Bassel-Duby; B N Fields; K L Tyler
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

4.  Crystal structure of glycoprotein C from Rift Valley fever virus.

Authors:  Moshe Dessau; Yorgo Modis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-14       Impact factor: 11.205

5.  Pathogenicity of antigenic variants of murine coronavirus JHM selected with monoclonal antibodies.

Authors:  J O Fleming; M D Trousdale; F A el-Zaatari; S A Stohlman; L P Weiner
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

6.  Virulence of La Crosse virus is under polygenic control.

Authors:  R S Janssen; N Nathanson; M J Endres; F Gonzalez-Scarano
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

7.  Mutagenesis of the La Crosse Virus glycoprotein supports a role for Gc (1066-1087) as the fusion peptide.

Authors:  Matthew L Plassmeyer; Samantha S Soldan; Karen M Stachelek; Susan M Roth; Julio Martín-García; Francisco González-Scarano
Journal:  Virology       Date:  2006-10-05       Impact factor: 3.616

8.  Sequence analysis of the medium (M) segment of Cache Valley virus, with comparison to other Bunyaviridae.

Authors:  C L Brockus; P R Grimstad
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

9.  Site-specific alteration of murine hepatitis virus type 4 peplomer glycoprotein E2 results in reduced neurovirulence.

Authors:  R G Dalziel; P W Lampert; P J Talbot; M J Buchmeier
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

10.  Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice.

Authors:  M Halevy; Y Akov; D Ben-Nathan; D Kobiler; B Lachmi; S Lustig
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.